Literature DB >> 9369317

Amino-terminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer's disease-affected brains: a possible role for apolipoprotein E in Alzheimer's disease.

Y Aizawa1, R Fukatsu, Y Takamaru, K Tsuzuki, H Chiba, K Kobayashi, N Fujii, N Takahata.   

Abstract

Amyloid deposits in Alzheimer's disease (AD) are composed of amyloid beta protein (A beta) and many other components called amyloid-associated proteins. Apolipoprotein E (apoE) is one of the most important amyloid-associated proteins. The role apoE plays in AD, however, is yet to be determined. In this study, we present the biochemical and histochemical nature of apoE in AD-affected brains using four monoclonal antibodies (mAbs) against apoE and newly established antibodies against the amino-terminal (anti-apoE-N), and carboxyl-terminal regions (anti-apoE-C) of apoE. Competitive ELISA and Western-blot analysis combined with thrombolytic digestion of apoE indicated that our four mAbs recognized at least two different epitopes within a 22-kDa amino-terminal domain of apoE. Using these mAbs and an anti-A beta mAb, double immunostaining showed that the majority of amyloid deposits were stained by both anti-apoE and anti-A beta mAbs, but the minority of them were detected only by either anti-apoE or anti-A beta mAbs. Differences in staining properties between anti-apoE-N and anti-apoE-C were that anti-apoE-C recognized both amyloid deposits and astrocytes similar to anti-apoE mAbs, but anti-apoE-N strongly stained only astrocytes. Preliminary semi-quantitative determinations of apoE in CSF and brain homogenate showed that the amount of apoE increased in AD and Creutzfeldt-Jakob disease brains compared to normal samples. Our immunological data, using antibodies specific for the amino and carboxyl termini of apoE, suggest that apoE may, in some circumstances, initiate plaque formation, and that apoE in amyloid deposits has at least part of its amino termini cleaved out.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9369317     DOI: 10.1016/s0006-8993(97)00640-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  8 in total

1.  Sodium dodecyl sulfate-resistant complexes of Alzheimer's amyloid beta-peptide with the N-terminal, receptor binding domain of apolipoprotein E.

Authors:  A A Golabek; E Kida; M Walus; C Perez; T Wisniewski; C Soto
Journal:  Biophys J       Date:  2000-08       Impact factor: 4.033

Review 2.  Progress toward identification of protease activity involved in proteolysis of apolipoprotein e in human brain.

Authors:  Marcos A Marques; Phillip A Owens; Keith A Crutcher
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

3.  Apolipoprotein E-related neurotoxicity as a therapeutic target for Alzheimer's disease.

Authors:  Marcos A Marques; Keith A Crutcher
Journal:  J Mol Neurosci       Date:  2003       Impact factor: 3.444

Review 4.  Apolipoprotein E is a prime suspect, not just an accomplice, in Alzheimer's disease.

Authors:  Keith A Crutcher
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

5.  Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases.

Authors:  N Sasaki; R Fukatsu; K Tsuzuki; Y Hayashi; T Yoshida; N Fujii; T Koike; I Wakayama; R Yanagihara; R Garruto; N Amano; Z Makita
Journal:  Am J Pathol       Date:  1998-10       Impact factor: 4.307

6.  The serine protease HtrA1 contributes to the formation of an extracellular 25-kDa apolipoprotein E fragment that stimulates neuritogenesis.

Authors:  Sonia Sanz Muñoz; Hongyun Li; Kalani Ruberu; Qian Chu; Alan Saghatelian; Lezanne Ooi; Brett Garner
Journal:  J Biol Chem       Date:  2018-02-02       Impact factor: 5.157

7.  Extracellular proteolysis of apolipoprotein E (apoE) by secreted serine neuronal protease.

Authors:  Irfan Y Tamboli; Dongeun Heo; G William Rebeck
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

Review 8.  Are apolipoprotein E fragments a promising new therapeutic target for Alzheimer's disease?

Authors:  Filomena Lo Vecchio; Paola Bisceglia; Bruno Pietro Imbimbo; Madia Lozupone; Raffaela Rita Latino; Emanuela Resta; Maurizio Leone; Vincenzo Solfrizzi; Antonio Greco; Antonio Daniele; Mark Watling; Francesco Panza; Davide Seripa
Journal:  Ther Adv Chronic Dis       Date:  2022-03-17       Impact factor: 5.091

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.